| 4.66 0.64 (15.92%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.72 |
1-year : | 6.68 |
| Resists | First : | 4.9 |
Second : | 5.72 |
| Pivot price | 3 |
|||
| Supports | First : | 3.29 |
Second : | 2.3 |
| MAs | MA(5) : | 3.41 |
MA(20) : | 2.95 |
| MA(100) : | 3.32 |
MA(250) : | 3.43 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 68.7 |
D(3) : | 55.4 |
| RSI | RSI(14): 79.3 |
|||
| 52-week | High : | 5.67 | Low : | 2.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SYRS ] has closed above the upper band by 25.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 166.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.91 - 4.93 | 4.93 - 4.95 |
| Low: | 3.89 - 3.91 | 3.91 - 3.92 |
| Close: | 4.63 - 4.66 | 4.66 - 4.69 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Thu, 07 Dec 2023
Healthcare Stocks on the Move Thursday: SLDB, UPC, SYRS, FBIO, ZVSA, WVE, OMER, SERA - InvestorsObserver
Thu, 07 Dec 2023
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene - Zacks Investment Research
Thu, 07 Dec 2023
Should You Accumulate Syros Pharmaceuticals Inc (SYRS) Stock Thursday Morning? - InvestorsObserver
Wed, 06 Dec 2023
Syros stock jumps after data for leukemia drug (NASDAQ:SYRS) - Seeking Alpha
Wed, 06 Dec 2023
Should You Buy Syros Pharmaceuticals Inc (SYRS) Stock After it Is Up 2.55% in a Week? - InvestorsObserver
Wed, 15 Nov 2023
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 55.2 (%) |
| Shares Short | 492 (K) |
| Shares Short P.Month | 611 (K) |
| EPS | 0.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | 0 % |
| Operating Margin | -858.2 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -126.9 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -6.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -122 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | 5.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.66 |
| Price to Sales | 11.15 |
| Price to Cash Flow | -0.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|